A novel method using nuclear magnetic resonance for plasma protein binding assessment in drug discovery programs.
Blood Proteins
/ chemistry
Drug Discovery
/ instrumentation
Drug Evaluation, Preclinical
Humans
In Vitro Techniques
Nuclear Magnetic Resonance, Biomolecular
Pharmaceutical Preparations
/ blood
Protein Binding
Recombinant Proteins
/ chemistry
Serum Albumin, Human
/ chemistry
Small Molecule Libraries
/ chemistry
Drug discovery
NMR
Plasma protein binding
Protein-ligand interaction
Screening
Journal
Journal of pharmaceutical and biomedical analysis
ISSN: 1873-264X
Titre abrégé: J Pharm Biomed Anal
Pays: England
ID NLM: 8309336
Informations de publication
Date de publication:
15 Apr 2019
15 Apr 2019
Historique:
received:
30
10
2018
revised:
28
01
2019
accepted:
29
01
2019
pubmed:
10
2
2019
medline:
10
7
2019
entrez:
10
2
2019
Statut:
ppublish
Résumé
A new methodology based on Nuclear Magnetic Resonance (NMR) was developed to determine plasma protein binding (PPB) of drug candidates in drug discovery programs. A strong correlation was found between the attenuation of NMR signals of diverse drugs in the presence of different plasma concentrations and their fraction bound (f
Identifiants
pubmed: 30738240
pii: S0731-7085(18)32370-7
doi: 10.1016/j.jpba.2019.01.049
pii:
doi:
Substances chimiques
Blood Proteins
0
Pharmaceutical Preparations
0
Recombinant Proteins
0
Small Molecule Libraries
0
Serum Albumin, Human
ZIF514RVZR
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
21-29Informations de copyright
Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.